Astract. The effect ofthe luteinizing hormonereleasing hormone (LHRH) agonist, NEth]LHRH (LHRHA), on luteinizing hormone (LH) bioactivity was assessed with a rat interstitial cell assay in four men during a 14-d treatment period. Biologic/ immunologic (B/I) ratios were unchanged initially with treatment but by day 12 had fallen to levels lower than basal values. Frequent sampling on day 12 revealed blunted gonadotropin responsiveness to LHRHA and absence of spontaneous LH pulsations. Despite continued administration of LHRHA, human chorionic gonadotropin administration resulted in elevated B/I ratios and testosterone levels. Further characterization ofthe serum immunoreactive LH by Sephadex chromatography revealed a later elution profile during treatment with LHRHA. Thus, LHRHA appears to act, in part, by modification of the bioactivity of LH in man. 
Introduction
Synthetic agonist analogs of luteinizing hormone-releasing hormone (LHRH)' decrease gonadal steroidogenesis. In animals, Receivedfor publication 5 August 1983 and in revisedform 13 
Results
Immunoactive serum gonadotropin and T levels. Mean gonadotropin and T levels initially increased but subsequently declined from peak levels on days 2 and 4, respectively, to a nadir on day 12 (Fig. 1) . Mean iLH levels remained higher than basal values at day 12 (P < 0.001); mean FSH and T levels were lower (P < 0.005 and P < 0.001, respectively). Sampling at 20-min intervals on day 12 revealed no spontaneous pulsations and a blunted response to scheduled injection of LHRHA. Administration of hCG increased both serum iLH and T concentrations.
LH bioassay. Basal biologic/immunologic (B/I) ratio ranged from 5.6 to 14 (Table I) . Following an initial rise, bioLH levels declined. By day 12, three of the four subjects exhibited bioLH levels lower than basal values; the fourth had returned to basal levels. The corresponding LH B/I ratio fell in each subject to values lower than the pretreatment determinations. hCG administration elevated both bioLH and B/I ratios in all subjects, reflecting the cross-reactivity ofthis gonadotropin in the bioassay and immunoassay systems employed.
Sephadex G-100 chromatography. The cross-reactivity of the LH-fl in our radioimmunoassay is about 4% in units of mass (insert, Fig. 2 ) and even lower in molar terms. The iLH obtained from all subjects during treatment eluted well after marker '25I-LH and near '25I-LH-fl. Off treatment, the iLH eluted with the marker. Fig. 2 shows data on subjects 1 and 2.
Results on the other two subjects revealed iLH eluted with a Kay of 0.33 and 0.34, respectively.
Discussion
The application of gonadotropin bioassays to the evaluation of pituitary-gonadal physiology has suggested that both gonadal steroids and LHRH may modulate gonadotropin bioactivity. The presence of estrogen has been associated with lower serum LH B/I ratios (6, 7) in humans. Conversely, the presence of T increases serum bioLH in the male rat. The mechanism is uncertain. However, Peckham and associates (8, 9) have demonstrated estrogen effects on chromatographic behavior of FSH in Rhesus monkeys and suggested that differences in sialic acid content of gonadotropins may be involved. The effect of the acute administration of native sequence LHRH on bioLH has also been examined. Dufau et al. (10) observed an increase in LH B/I ratio after LHRH in both preand postmenopausal women but not in normal men. A biphasic increase in LH B/I ratio was noted in normal and postmenopausal women by Sawyer-Steffan et al. (1 1). These findings, in conjunction with the known heterogeneity of gonadotropins (12) , suggest the presence in the pituitary of distinct forms of LH with biochemical or immunochemical differences.
This study examines the effect of an LHRH agonist analog on LH secretion in man with the use ofan LH bioassay. Although the LH B/I ratios in this study were higher than unity before treatment, this phenomenon has been observed previously (10, 1 1). LHRHA-induced LH release initially stimulates T production, but, by the twelfth day of treatment, bioLH is diminished despite clearly elevated iLH levels, an observation consistent with recent findings (13) . Frequent sampling discloses a markedly altered pattern of LH release; no spontaneous pulsations occur, and the response to injection of LHRHA is blunted. Exogenous gonadotropin stimulates T production despite continued administration of LHRHA. These findings, coupled with a demonstrable change in the elution profile of iLH on Sephadex G-100 chromatography, strongly suggest that LHRHA induces the pituitary to release an immunoreactive LH with diminished bioactivity.
We believe that the effects on bioactivity and the chromatographic changes observed are a direct effect of treatment with LHRHA rather than an effect ofandrogen depletion. Subject 4 had a low B/I ratio on day 12 despite essentially normal T concentration. In addition, similar elution profiles have been observed in two other men who were chronically treated with 500 ,g LHRHA daily and 100 mg i.m. testosterone enanthate every 2 wk, at a time that their serum T concentrations were 5.6 and 11 ng/ml, respectively (data not shown).
Possible alterations of LH that could account for these findings include (a) changes in carbohydrate content (14, 15) 
